Biovalys
Biovalys is a private Bangkok-based biopharmaceutical company, founded in 2010, specializing in vaccines and biological products with 51-100 employees. The company operates in the Thai and regional Southeast Asian biologics market, though its product portfolio and commercial stage are not documented in available data.
- Company typePrivate
- Founded2010
- HeadquartersBangkok, Thailand
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biovalys does
Biovalys is a private, for-profit biopharmaceutical company headquartered in Bangkok, Thailand, founded in 2010. The company specializes in vaccines and biological products, positioning it within the biologics segment of the pharmaceutical industry, likely serving both Thai domestic and regional Southeast Asian markets. With 51-100 employees, Biovalys operates at a small-to-mid scale typical of emerging-market biopharma firms focused on affordable vaccine production and biological therapeutics.
The company's business model and product portfolio cannot be characterized with specificity from the available data. No product names, pipeline candidates, technology platforms, pricing models, customer segments, or distribution channels are disclosed. The company website (biovalys.com) was non-functional at the time of data collection, displaying only a verification loader page rather than substantive content. This absence of accessible corporate communications material precludes verification of operational status, product commercialization stage, partnerships, or revenue activities.
Given the 14-year operating history and Thailand-based biologics focus, Biovalys likely participates in vaccine manufacturing, biosimilar development, or biological R&D for public health or veterinary applications—common segments for Thai biopharma. However, no funding rounds, regulatory milestones, leadership information, customer relationships, or technology details are available in the input to substantiate these inferences. The data gap is substantial: there is insufficient evidence to characterize the company's commercial stage, revenue generation, or strategic direction.
Biovalys firmographics
Firmographics- Name
- Biovalys
- Website
- https://biovalys.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Biovalys is a private Bangkok-based biopharmaceutical company, founded in 2010, specializing in vaccines and biological products with 51-100 employees. The company operates in the Thai and regional Southeast Asian biologics market, though its product portfolio and commercial stage are not documented in available data.
- Ownership category
- akta.pro rank
Biovalys industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
- akta.pro secondary industry
- Other Recombinant Protein Biosimilars (non-mAb, non-hormone) (HLAIAFAL)
Keywords
Where Biovalys is headquartered
LocationHeadquarters
- HQ city
- Bangkok
- HQ country
- Thailand
- HQ region
- Asia
Markets served
Biovalys business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Biovalys product offering
Product offeringCore offering
Biovalys is a biopharmaceutical company that develops and produces vaccines and biological products. The company operates in the pharmaceutical sector with a focus on biological therapeutics and vaccine solutions for healthcare applications.
Differentiator
Problem solved
Functional benefit
Companies that use Biovalys
Customer profileIdeal customer profiles1 record
Biovalys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Biovalys competitors and assessment
Company assessmentBroad incumbents
- Bharat Biotech: Indian vaccine and biotherapeutics developer with a large global export footprint. Comparable as an emerging-market biopharma specializing in vaccines and biologics.
- SK Bioscience: Korean vaccine and biopharmaceutical manufacturer with global commercial partnerships. Comparable as an established Asian vaccine and biologics player pursuing international expansion.
- Biological E: Indian vaccines and biologics manufacturer with WHO prequalification supplying global public-health programs. Comparable in focus on cost-competitive vaccines and biologics for emerging markets.
- Hualan Biological Engineering: Chinese plasma-derived products and vaccine manufacturer with large-scale production capabilities. Comparable in product category (biological products/vaccines) and emerging-market scale.
- GC Biopharma: Korean biopharmaceutical company with an established vaccines and blood-products portfolio. A relevant incumbent peer given its scale in Asia and overlap in biological products.
- Sinovac Biotech: China-based vaccine manufacturer with a broad commercial portfolio across Asia and emerging markets. Comparable in product focus (vaccines) and emerging-market commercial orientation.
Emerging players
- Panacea Biotec: Indian biopharmaceutical company focused on vaccines and biosimilars. Comparable in its combination of vaccine and biosimilar strategy aimed at emerging markets.
- LG Chem Life Sciences: Korean specialty biopharmaceutical division developing biologics and vaccines. Comparable as an Asian player building a biologics and vaccine pipeline with regional ambitions.
Direct peers
- BioNet-Asia: Thailand-based vaccine manufacturer with a regional export footprint. Comparable in product category (vaccines), geography, and scale, and competes for the same ASEAN public-sector tenders.
Regional players
- Siam Bioscience: Thai biopharmaceutical manufacturer with government backing producing vaccines and biologics. Most directly comparable as a domestic Thai peer competing for the same local and regional public-health contracts.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
Biovalys social profiles
Digital presenceBiovalys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biovalys leadership team
Management profileNumber of profiles
Biovalys funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biovalys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biovalys
What does Biovalys do?
Biovalys is a biopharmaceutical company that develops and produces vaccines and biological products. The company operates in the pharmaceutical sector with a focus on biological therapeutics and vaccine solutions for healthcare applications.
When was Biovalys founded?
Biovalys was founded in 2010. It employs 51 to 100 people.
Where is Biovalys based?
Biovalys is headquartered in Bangkok, Thailand, in the Asia region.
Who are Biovalys's main competitors?
Broad incumbents on record are Bharat Biotech, SK Bioscience, Biological E, Hualan Biological Engineering, GC Biopharma and Sinovac Biotech. Emerging players are Panacea Biotec and LG Chem Life Sciences. BioNet-Asia is listed as a direct peer. Siam Bioscience is listed as a regional player.
Does Biovalys have an API?
No public API is recorded for Biovalys.
What industry is Biovalys in?
Biovalys's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAIAFAL, Other Recombinant Protein Biosimilars (non-mAb, non-hormone). Its NAICS code is 325414 and its SIC code is 2836.